In conclusion, the STING agonist combined with RG3 enhances cisplatin sensitivity in SGC‐7901/DDP cells by inhibiting their proliferation, migration, and tube formation, effectively reversing cisplatin resistance in gastric cancer cells. Here, STING1 is linked to gastric cancer.